What is the virus that is viral fever of humans and primates and that Triazavirin could have a potential application?
Triazavirin Triazavirin (TZV) is a broad-spectrum antiviral drug developed in Russia through a joint effort of Ural Federal University, Russian Academy of Sciences, Ural Center for Biopharma Technologies and Medsintez Pharmaceutical. It has an azoloazine base structure, which represents a new structural class of non-nucleoside antiviral drugs. It was originally developed as a potential treatment for pandemic influenza strains such as H5N1, and most of the testing that has been done has focused on its anti-influenza activity. However triazavirin has also been found to have antiviral activity against a number of other viruses including tick-borne encephalitis, and is also being investigated for potential application against Lassa fever and Ebola virus disease.
Xenotropic murine leukemia virus-related virus Xenotropic murine leukemia virus-related virus (XMRV) is "a laboratory-derived mouse virus that was generated through recombination between two endogenous murine retroviruses during propagation of a prostate cancer xenograft in the mid-1990's". The chimeric virus was first described in 2006 as an apparently novel retrovirus and potential human pathogen. Initial reports erroneously linked the virus to prostate cancer and later to chronic fatigue syndrome (CFS), leading to considerable interest in the scientific and patient communities, investigation of XMRV as a potential cause of multiple medical conditions, and public health concerns about the safety of the donated blood supply.